Tirzepatide, a recently popular weight-loss drug, is advised for individuals with certain cases of type 2 diabetes and obesity, according to Zuellig Pharma, a pharmaceutical company.
The drug, fondly known as “Tirz,” recently gained popularity due to its dual-action mechanism, which can help regulate both blood sugar and body weight.
In an email interview, Zuellig Pharma said that tirzepatide (brand name: Mounjaro), for instance, targets both GIP and GLP-1—hormones that help regulate blood sugar after meals—to support blood sugar control and weight management.
Support authors and subscribe to content
This is premium stuff. Subscribe to read the entire article.
Login if you have purchased
